These findings, together with the fact that abnormal expression of NFE2L3 can also lead to metabolic reprogramming by affecting the expression of glucose transporter GLUT1 in colorectal cancer cells (Aono et al., 2019) and Nfe2l3 was identified as one of the five most variable genes in the AOM/DSS model (Suzuki et al., 2007), suggest that NFE2L3 may play a crucial role in the early stages of colon cancer development, although distinct phenotypes were not observed in Nfe2l3 knockout mice. The gene discussed is NFE2L3; the disease is malignant colon neoplasm.